Abaloparatide - Ipsen/Radius Health

Drug Profile

Abaloparatide - Ipsen/Radius Health

Alternative Names: Abaloparatide patch; Abaloparatide-SC; Abaloparatide-TD; BA-058; BA-058-SC; BA-058-TD; BIM-44058; Eladynos; ITM-058; PTHrP; Synthetic human parathyroid hormone 37-70 analogue - Ipsen; TYMLOS

Latest Information Update: 09 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 3M Drug Delivery Systems; Biomeasure Inc; Ipsen
  • Developer Radius; Radius Health Inc.; Teijin Pharma
  • Class Calcium regulators; Osteoporosis therapies; Peptide hormones
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Postmenopausal osteoporosis

Highest Development Phases

  • Marketed Postmenopausal osteoporosis
  • Phase III Male osteoporosis

Most Recent Events

  • 01 Oct 2018 Radius Health receives approval from the US FDA for sNDA to include data from the ACTIVExtend trial
  • 24 Jul 2018 The Committee for Medicinal Products for Human Use (CHMP) of EMA issues negative trend vote on the re-examination of abaloparatide for treatment of Postmenopausal osteoporosis
  • 01 Jul 2018 Radius Health initiates enrolment in a clinical trial for Postmenopausal osteoporosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top